Engineering T cell memory for antitumor immunity.
Trends Pharmacol Sci
; 43(1): 1-3, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-34785086
ABSTRACT
Cancer therapy with the T cell growth factor interleukin (IL)-2 is limited by low response rates and toxicity. Multiple protein engineering strategies have attempted to improve IL-2 therapy, typically through enhanced IL-2 receptor (IL-2R) binding. Intriguingly, Mo et al. show that an IL-2R partial agonist may dramatically improve IL-2 responses by altering T cell differentiation.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
T-Lymphocytes
/
Receptors, Interleukin-2
/
Interleukin-2
/
Immunologic Memory
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Trends Pharmacol Sci
Year:
2022
Type:
Article
Affiliation country:
United States